Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder

Neurotech Pharmaceuticals’ surgically implanted cell and gene therapy, Encelto, is now FDA approved to treat macular telangectasia type 2 (MacTel). It’s the first therapy for this rare retinal degeneration disorder.

The post Gene Therapy in an Implant: Neurotech Lands First FDA Approval in Rare Vision Disorder appeared first on MedCity News.